Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca (AZN) Discontinues Brazikumab Development
11:50am, Thursday, 01'st Jun 2023
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
AstraZeneca drug combo gets US nod to treat a type of prostate cancer
02:50am, Thursday, 01'st Jun 2023
AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant pro
AstraZeneca to stop developing Crohn's disease drug
02:43am, Thursday, 01'st Jun 2023
British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
08:50am, Monday, 29'th May 2023
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
09:15am, Sunday, 28'th May 2023
Merck and AstraZeneca both appear to be well-positioned for the future. Both boast above-average dividends that look to remain viable.
AstraZeneca's drug combo shows positive results in late-stage cancer trial
02:48am, Friday, 26'th May 2023
AstraZeneca said on Friday a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or r
AstraZeneca hails the findings from cancer combination trial
02:41am, Friday, 26'th May 2023
AstraZeneca PLC (LSE:AZN) has hailed the potential of a highly targeted combination of its own drugs with chemotherapy in the battle against endometrial cancer. This followed the read-out from the D
AstraZeneca: Think Medium-To-Long Term
11:02am, Thursday, 25'th May 2023
AstraZeneca's price has moved sideways in the past month, after showing good progress for some time. A look at its numbers reveals that it is going strong, and will continue to do so in the foreseeabl
3 Undervalued Pharma Stocks to Buy for High Total Returns
11:27am, Friday, 19'th May 2023
Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors.
The 7 Next Trillion-Dollar Companies to Invest in Now
05:43pm, Thursday, 18'th May 2023
In the last decade, few companies have touched the magic trillion-dollar valuation. Apple (NASDAQ: AAPL ), Amazon (NASDAQ: AMZN ), and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ) are the names worth ment
Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?
04:46pm, Tuesday, 16'th May 2023
We continue our analytics coverage of AstraZeneca PLC with a "hold" rating for the next 12 months. AstraZeneca's revenue for the first three months of 2023 was $10.88 billion, down 2.9% from the previ
Is AstraZeneca Stock a Buy for Growth Investors?
08:00am, Sunday, 14'th May 2023
AstraZeneca delivered solid results to its shareholders in the first quarter. The British drugmaker spends nearly a quarter of its revenue on R&D.
3 Low-Volatility Stocks for a Stable Investment Strategy
06:46am, Saturday, 06'th May 2023
With another rate hike by the Fed, the markets remain in an uncertain zone. In all probability, the Fed will pause on rate hikes.
How To Collect Income With A Covered Call On Breakout Stock AstraZeneca | IBD
01:47pm, Wednesday, 03'rd May 2023
AstraZeneca, breakout stock and market outperformer, is trading in a buy zone. Here's how you can get paid for holding the stock long term.
Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
12:55pm, Wednesday, 03'rd May 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
